Kandrozid (Candesartan Cilexetil)

Candesartan cilexetil is a prodrug that is converted to candesartan, which selectively blocks the angiotensin II type 1 (AT1) receptor. This inhibition prevents angiotensin II‑induced vasoconstriction and aldosterone release, resulting in vasodilation, reduced sodium retention, and lower systemic blood pressure.

The appropriate dose of Kandrozid is determined by the prescribing clinician based on the patient’s medical condition, response to therapy, and renal function. Dosage adjustments are made individually; patients should follow the prescriber’s instructions and not alter the dose on their own.

Kandrozid is classified as Pregnancy Category D, indicating evidence of fetal risk. It should be avoided during pregnancy unless the potential benefit justifies the risk. Limited data are available for breastfeeding; therefore, use is generally not recommended without a thorough risk‑benefit assessment by a healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity of Kandrozid. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Kandrozid belongs to the angiotensin II receptor blocker (ARB) class, which offers blood‑pressure control similar to ACE inhibitors but with a lower incidence of cough and angio‑edema. Compared with calcium‑channel blockers or diuretics, ARBs provide a distinct mechanism focused on the renin‑angiotensin system, often used when those alternatives are unsuitable.

Kandrozid should be stored at ambient temperature, preferably below 25 °C, in its original packaging. Protect the tablets from moisture, excessive heat, and direct sunlight to maintain product stability throughout its shelf life.

Kandrozid is taken orally, usually once daily, with or without food as directed by the prescriber. Swallow the tablet whole with a glass of water; do not crush, split, or chew unless specifically instructed by a healthcare professional.

Serious risks, though uncommon, include hyperkalaemia, acute kidney injury, severe hypotension, and angio‑edema. Patients should be monitored for signs such as swelling of the face or throat, rapid weight gain, or a sudden drop in blood pressure, and seek immediate medical attention if these occur.

Kandrozid is contraindicated in patients with known hypersensitivity to candesartan or any component of the formulation, those with severe hepatic impairment, and individuals who are pregnant. It should also be avoided in patients taking aliskiren if they have diabetes or moderate to severe renal impairment.